Christopher R. Wellaway

Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation

Omer Gilan, Inmaculada Rioja, Kathy Knezevic et al. · Science · 2020 · 428 citations · Full text

Life Sciences, Immunology, Pharmacology +13

Click chemistry enables preclinical evaluation of targeted epigenetic therapies

Dean Tyler, Johanna Vappiani, Tatiana Cañeque et al. · Science · 2017 · 143 citations · Full text

Medicine, Oncology, Pharmacology +17

Discovery of a Bromodomain and Extraterminal Inhibitor with a Low Predicted Human Dose through Synergistic Use of Encoded Library Technology and Fragment Screening

Christopher R. Wellaway, Dominique Amans, Paul Bamborough et al. · Journal of Medicinal Chemistry · 2020 · 71 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype

Christopher R. Wellaway, Paul Bamborough, Sharon G. Bernard et al. · Journal of Medicinal Chemistry · 2020 · 46 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Conformationally rigid pyrazoloquinazoline α-amino acids: one- and two-photon induced fluorescence

Jonathan D. Bell, Alexander H. Harkiss, David Nobis et al. · Chemical Communications · 2020 · 27 citations · Full text

Natural Sciences, Biochemistry, Medicinal Chemistry +17